Ann: $15m Placement Completed-Including US Cornerstone Investor, page-5

2 major milestones ticked by ACW today which pl;aces it as a serious multibagger opportunity. PHS2 interim data shows no adverse effects and to continue trials of XanADu at same dose plus the data also supports development of Xanamem in other indications like diabetic cognitive impairment. Top this info with leading US biotech fund Biotechnology Value Fund to take a cornerstone investment of a 19.9% position in ACW at a 13.4% premium. A big vote of confidence in Actinogen on current interim data plus moving forward on other indications. The second half of 2018 and 2019 are going to be major for ACW with major upside potential here. I believe this is shaping up as the biotech of 2018/2019.